At the Core of the Latest Pharm-to-Table Dispute: Which GLP-1 Was Hims Preferring?

Reading Bob Herman’s new STAT piece about the newest PBM tactic -- something called “rebate credits” -- is kind of tough sledding. The source materials aren’t made available, so his

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.

So there won’t be news this week on the government’s opening offer** around price controls for the first 10 medicines selected under the Inflation Reduction Act. Companies will get the